CD39 expression on immune cells predicts methotrexate response in rheumatoid arthritis patients
Turkish Journal of Medical Sciences · 26.10.2023 · 53 (5) · 1075-1083
DOI: 10.55730/1300-0144.5672 ↗Kurz gefasst
Fachartikel in der Zeitschrift Turkish Journal of Medical Sciences, online erschienen am 26.10.2023. Verfasst von Barış Boral und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Adana Health Practice and Research Center, University of Health Sciences, Adana, Turkiye. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Methotrexate, Apyrase, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background/aim: Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting mostly small joints, such as hand and foot joints symmetrically with irreversible joint destruction. In this study, the relationship between CD39 expression and the treatment response of RA patients was examined to investigate its potential as a biomarker that demonstrates treatment response. Materials and methods: This study included 77 RA patients and 40 healthy controls (HC). The RA patients were divided into 2 groups based on their response to RA treatment, those with a good response to methotrexate (MTX) monotherapy and those with an inadequate response based on the American College of Rheumatology and the European League Against Rheumatism response criteria. Various immunological parameters and Disease Activity Score in 28 Joints (DAS28) were examined between the groups using the Student?s t-test.
Results
The monocytic myeloid-derived suppressor cell (M-MDSC) percentage was higher in the RA patient group versus the HC group. The CD39 expression in the T lymphocytes were higher in patients that responded well to the MTX compared to those showing inadequate response. Additionally, s negative correlation was found between the DAS28 and CD39 in the T cells.
Conclusion
The results showed that the improvement in treatment response to the therapy in RA patients could be because of the enhancement in the CD39/adenosine (ADO) pathway. Therefore, therapies targeting the CD39/ADO pathway in T cells may improve RA treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Adana Health Practice and Research Center, University of Health Sciences, Adana, Turkiye.
- Department of Immunology, Prof. Dr. Cemil Taşcıoğlu City Hospital, University of Health Sciences, İstanbul, Turkiye.
- Department of Medical Microbiology, Faculty of Medicine, Çukurova University, Adana, Turkiye.
- Department of Immunology, Faculty of Medicine, Çukurova University, Adana, Turkiye.
- Division of Rheumatology, Department of Internal Medicine, Adana City Training and Research Hospital, Adana Turkiye.
- Department of Immunology, Ankara City Hospital, University of Health Sciences, Ankara, Turkiye.
ORCID-Profile: Barış Boral, İbrahim Tuncer, Filiz Kibar, Salih Çetiner, Suade Özlem Badak, Emrah Salman, Emrah Koç, Eren Erken, Akgün Yaman
Zitieren
APA
Boral, B., Tuncer, İ., Kibar, F., Çetiner, S., Badak, S. Ö., Salman, E., Koç, E., Erken, E., & Yaman, A. (2023). CD39 expression on immune cells predicts methotrexate response in rheumatoid arthritis patients. Turkish Journal of Medical Sciences, 53(5), 1075-1083. https://doi.org/10.55730/1300-0144.5672
Vancouver
Boral B, Tuncer İ, Kibar F, Çetiner S, Badak SÖ, Salman E, et al. CD39 expression on immune cells predicts methotrexate response in rheumatoid arthritis patients. Turkish Journal of Medical Sciences. 2023;53(5):1075-1083. doi:10.55730/1300-0144.5672
BibTeX
@article{Boral2023,
author = {Boral, Barış and Tuncer, İbrahim and Kibar, Filiz and Çetiner, Salih and Badak, Suade Özlem and Salman, Emrah and Koç, Emrah and Erken, Eren and Yaman, Akgün},
title = {CD39 expression on immune cells predicts methotrexate response in rheumatoid arthritis patients},
journal = {Turkish Journal of Medical Sciences},
year = {2023},
volume = {53},
number = {5},
pages = {1075--1083},
doi = {10.55730/1300-0144.5672}
}
EUVIMED